Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2008
03/18/2008CA2319359C Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers
03/18/2008CA2315927C Oral pharmaceutical pulsed release dosage form
03/18/2008CA2315395C Compositions and methods for treatment of alopecia
03/18/2008CA2298493C Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis
03/18/2008CA2293705C Process for obtaining quinapryl hydrochloride and solvates useful for isolating and purifying quinapryl hydrochloride
03/18/2008CA2288705C Use of quinazoline compounds for the treatment of polycystic kidney disease
03/18/2008CA2275889C Formulation and method for treating neoplasms by inhalation
03/18/2008CA2275663C Pharmaceutical compositions comprising .alpha.-adrenergic agonists for the treatment of fecal incontinence
03/18/2008CA2266645C Polycarboxylic based cross-linked copolymer
03/18/2008CA2264739C Inhibition of nuclear transcription factor nf-kb by caffeic acid phenethyl ester (cape), derivatives of cape, capsaicin (8-methyl-n-vanillyl-6-nonenamide) and resiniferatoxin
03/18/2008CA2219659C Rapamycin derivatives
03/18/2008CA2193235C The preparation of fusidic acid tablets
03/18/2008CA2181073C Tissue-specific enhancer active in prostate
03/18/2008CA2167980C Cgrp antagonist used in a cosmetic composition; pharmaceutical or dermatologic composition produced
03/18/2008CA2121689C 1.alpha.,24(s)-dihydroxy vitamin d2, its formation and use
03/18/2008CA2102494C A pharmaceutical composition containing a defined lipid system
03/14/2008CA2613119A1 Compositions and methods for enhancing accretion in skeletal muscle
03/14/2008CA2568354A1 Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
03/13/2008WO2008031113A2 Improved method for inhibition of neovascularization
03/13/2008WO2008031105A1 Polymeric guanidine salt-based germicides
03/13/2008WO2008031090A1 Compositions for the treatment of hoof diseases
03/13/2008WO2008031087A1 Compositions comprising a c2-c14 carboxylic acid and a surfactant for treating hoof diseases
03/13/2008WO2008031048A2 Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
03/13/2008WO2008031032A2 Compounds for and methods of treating insulin resistance and inflammation
03/13/2008WO2008031028A2 Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
03/13/2008WO2008031017A2 Supramolecular metallic complexes exhibiting both dna binding and photocleavage
03/13/2008WO2008031014A1 Method for reducing or alleviating inflammation in the digestive tract
03/13/2008WO2008031013A1 Method for treating inflammatory diseases of the digestive tract
03/13/2008WO2008030949A2 Stable polyunsaturated fatty acid emulsions and methods for inhibitintg, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
03/13/2008WO2008030925A2 Antimicrobial colorants
03/13/2008WO2008030902A1 Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function
03/13/2008WO2008030892A2 Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
03/13/2008WO2008030891A2 Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
03/13/2008WO2008030887A2 Methods for designing parp inhibitors and uses thereof
03/13/2008WO2008030883A2 Treatment of cancer
03/13/2008WO2008030853A2 Combination therapy for human immunodeficiency virus infection
03/13/2008WO2008030843A1 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
03/13/2008WO2008030838A2 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist biological activity
03/13/2008WO2008030836A2 Bcl inhibitors treating platelet excess
03/13/2008WO2008030830A2 Sustained-release composition and method of use thereof
03/13/2008WO2008030803A2 Hiv inhibitors
03/13/2008WO2008030795A2 Compositions and methods for inhibition of tyrosine kinases
03/13/2008WO2008030752A2 Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
03/13/2008WO2008030744A2 Inhibitors of c-met and uses thereof
03/13/2008WO2008030651A1 Combinations containing a 4-acylaminopyridine derivative
03/13/2008WO2008030638A2 Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
03/13/2008WO2008030626A2 Skin compositions containing hydrocortisone
03/13/2008WO2008030624A2 Nanoparticles for two-photon activated photodynamic therapy and imaging
03/13/2008WO2008030618A1 Benzo-fused compounds for use in treating metabolic disorders
03/13/2008WO2008030617A2 Cancer therapy with cantharidin and cantharidin analogs
03/13/2008WO2008030604A2 Treatment, prevention, and reversal of alcohol-induced brain disease
03/13/2008WO2008030595A2 Treatment, prevention, and reversal of alcohol-induced liver disease
03/13/2008WO2008030579A2 Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
03/13/2008WO2008030567A2 Dry powder compound formulations and uses thereof
03/13/2008WO2008030557A2 Compositions and methods for enhancing transport through mucus
03/13/2008WO2008030536A2 Process of epilobium species for treatment of hormone balance in warm blooded animals, and method of manufacturing
03/13/2008WO2008030532A2 Substituted oxazole ketone modulators of fatty acid amide hydrolase
03/13/2008WO2008030524A2 Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
03/13/2008WO2008030520A1 Heterocyclic gpr40 modulators
03/13/2008WO2008030512A2 Polystyrene sulfonate polymer tablets, their preparation and use
03/13/2008WO2008030511A2 Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
03/13/2008WO2008030466A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use
03/13/2008WO2008030448A1 Phenethylamide derivatives with kinase inhibitory activity
03/13/2008WO2008030412A2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
03/13/2008WO2008030408A2 Proteomimetic compounds as inhibitors of the interaction of a nuclear receptor with coactivator peptides
03/13/2008WO2008030391A2 Difluorinated piperidines for treatment of alzheimer's disease and related conditions
03/13/2008WO2008030390A2 Ophthalmic compositions for treating ocular hypertension
03/13/2008WO2008030389A2 Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
03/13/2008WO2008030382A1 Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
03/13/2008WO2008030373A2 L- oddc prodrugs for cancer
03/13/2008WO2008030369A1 Inhibitors of 5 -lipoxygenase activating protein ( flap)
03/13/2008WO2008030361A2 Wake-up on time dietary supplement and method of use
03/13/2008WO2008030359A2 Topical compositions
03/13/2008WO2008030283A1 Methods of diagnosing and treating complications of pregnancy
03/13/2008WO2008030239A1 RNA INTERFERENCE MEDIATED INHIBITION OF HISTONE DEACETYLASE (HDAC) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
03/13/2008WO2008030161A1 Pharmaceutical composition comprising candesartan cilexetil
03/13/2008WO2008030158A1 Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
03/13/2008WO2008030141A1 Use of nifuroxazide in the form of a component of a combined drug therapy for treating diseases associated with helicobacter pylori and a curing method for eradicating a causative agent
03/13/2008WO2008030119A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
03/13/2008WO2008030118A1 Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
03/13/2008WO2008030108A1 Animal production
03/13/2008WO2008029949A1 Method and composition for promoting gastrointestinal bicarbonate secretion
03/13/2008WO2008029924A1 Cyclic aminoalkylcarboxamide derivative
03/13/2008WO2008029912A1 Compound having benzamide skeleton and cyclooxygenase (cox-1)-selective inhibitory activity
03/13/2008WO2008029909A1 Composition comprising reduced coenzyme q10 and lysolecithin
03/13/2008WO2008029907A1 Hypertension-ameliorating agent
03/13/2008WO2008029882A1 2-alkyl-6-(pyrazolopyridin-4-yl)pyridazinone derivative, addition salt thereof, and pde inhibitor comprising the derivative or the salt as active ingredient
03/13/2008WO2008029876A1 Salt of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1- methylpyridin-2(1h)-one and crystal thereof
03/13/2008WO2008029871A1 Nerve fiber degeneration inhibitor
03/13/2008WO2008029868A1 Ocular fibrous neovascularization inhibitor
03/13/2008WO2008029846A1 Lipase inhibitor
03/13/2008WO2008029829A1 Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient
03/13/2008WO2008029825A1 Imidazole derivative
03/13/2008WO2008029790A1 Novel nucleic acid
03/13/2008WO2008029763A1 Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent
03/13/2008WO2008029619A1 Ena antisense oligonucleotide having sequence-specific action
03/13/2008WO2008029599A1 Magnetic particles and process for their production
03/13/2008WO2008029511A1 Insulin sensitivity improving agent
03/13/2008WO2008029493A1 Nerve fiber degeneration inhibitor
03/13/2008WO2008029414A2 Use of transcription factor inhibitor in the manufacture of a medicament
1 ... 3339 3340 3341 3342 3343 3344 3345 3346 3347 3348 3349 3350 3351 3352 3353 3354 3355 3356 3357 3358 3359 ... 7860